On November 4, 2024 ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA),an AI-driven biotherapeutic research and technology company, reported the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts (Press release, ImmunoPrecise Antibodies, NOV 4, 2024, View Source [SID1234647660]). This exclusive gathering will highlight IPA’s latest advancements in AI-driven design, biologics innovation, and strategic technological developments.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Highlights of TECHDAY:
•
Presentation by Dr. Dirk Van Hyfte: Dr. Van Hyfte will present "Accelerating Drug Discovery with LENSai: A Comprehensive Solution." He will showcase LENSai, BioStrand’s revolutionary platform, and discuss how it transforms drug discovery by integrating biotechnology, biotherapeutics, and artificial intelligence. Key topics include using HYFT Universal Fingerprints to revolutionize multi-omics and data integration while accelerating drug discovery, development and optimization with AI-driven insights.
•
LENSai Demo: A live demonstration of the LENSai platform, showcasing its capabilities in accelerating and enhancing the discovery and design of therapeutic antibodies through AI-driven insights.
•
Presentation by Dr. Shuji Sato: Dr. Sato will present IPA’s B Cell Discovery Platform and discuss its integration with the company’s advanced AI and NGS workflows for highly efficient hit expansion. This process includes:
•
Fast analysis of complete NGS repertoires
•
Multimodal feature extraction that combines sequence, structure, and large language model (LLM) embeddings to deliver enhanced insights into sample diversity.
•
Add-ons that complement outputs from phage display, B-cell, and hybridoma technologies, enabling the retrieval of antibody sequences with characteristics similar to known binders.
•
Fireside Chat: Disruptive Dialogue: Empowering Drug Discovery Through Seamless Data Integration and AI-Powered Insights
Participants:
•
Dr. Dirk Van Hyfte, Head of Innovation and Co-founder, BioStrand (IPA)
•
Jeff Fried, Director of Platform Strategy and Innovation, InterSystems
This discussion will explore how vector search intelligence is at the core of the LENSai platform, seamlessly integrated with the InterSystems IRIS data platform to deliver precise, scalable solutions that accelerate antibody discovery, enhance accuracy, and increase candidate diversity.
AI-Driven Drug Discovery Summit USA 2024
Additionally, earlier that same week at the AI-Driven Drug Discovery Summit USA 2024, IPA will participate in another fireside chat titled Beyond conventional biologics: the intersection of machine learning and biological engineering to invent.
Participants at the AI-Driven Drug Discovery Summit USA 2024:
•
Adam Root, Vice President and Head of Protein Sciences, Generate Biomedicines
•
Dr. Dirk Van Hyfte, Head of Innovation and Co-founder, BioStrand (IPA)
The chat will focus on the integration of artificial intelligence and machine learning with wet lab infrastructure to accelerate biologics development.
A recorded webcast of the TECHDAY presentations will be available in the Investors section of the IPA website under "Events and Presentations" at ir.ipatherapeutics.com.